Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia

This study aimed to identify biomarkers for clinical outcomes in a phase 3 clinical study of blinatumomab or chemotherapy in adults with Philadelphia chromosome-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Patients were randomized 2:1 to receive blinatumomab, a BiTE(R) therapy, for 4 weeks (9 mu g/day cycle 1 week 1, 28 mu g/day thereafter) every 6 weeks, or chemotherapy. Baseline blood samples were evaluated to identify biomarkers prognostic (both treatment groups) or predictive (either treatment groups) for overall survival, event-free survival, hematologic remission, minimal residual disease (MRD) response, duration of response, or adverse events. Baseline values were balanced between treatment groups. Prognostic biomarkers were platelets, tumor burden, and percentage of T cells: each 1-log increase in platelets at baseline was prognostic for improved 6-month survival; lower tumor burden was prognostic for hematologic remission; and a higher percentage of CD3(+) T-cells was prognostic for MRD response. Consistent with the BiTE mechanism of action, higher percentage of CD45(+) CD3(+) CD8(+) T cells was associated with hematologic remission following blinatumomab. No examined biomarkers were significant for the risk of grade >= 3 adverse events. Incorporating baseline biomarkers into future studies may help to identify subgroups most likely to benefit from blinatumomab.

Automated summary

This study identified platelets, tumor burden, and percentage of T cells as prognostic and predictive biomarkers for outcomes in adults with Philadelphia chromosome-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia receiving blinatumomab or chemotherapy. Adjusting these biomarkers may help in identifying subgroups most likely to benefit from blinatumomab treatment.